Search

Your search keyword '"Haslam A"' showing total 25,074 results

Search Constraints

Start Over You searched for: Author "Haslam A" Remove constraint Author: "Haslam A"
25,074 results on '"Haslam A"'

Search Results

101. Sotorasib in KRASG12C mutated lung cancer: Can we rule out cracking KRAS led to worse overall survival?

102. Design, power, and alpha levels in randomized phase II oncology trials

103. Frequency and Characteristics of Trials Using Medical Writer Support in High-Impact Oncology Journals.

104. An analysis of studies pertaining to masks in Morbidity and Mortality Weekly Report: Characteristics and quality of all studies from 1978 to 2023

105. Multiple myeloma: challenges with deciding the optimal sequencing strategy

106. Somatosensory Impairment and Chronic Pain Following Stroke: An Observational Study

107. Comparability of control and comparison groups in studies assessing long COVID

108. Umbrella review of basket trials testing a drug in tumors with actionable genetic biomarkers.

109. A systematic review of basket and umbrella trials in oncology: the importance of tissue of origin and molecular target.

110. Eventual success rate and predictors of success for oncology drugs tested in phase I trials.

112. Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial

114. Saliva, Plasma, and Multifluid Metabolomic Signatures of Periodontal Disease, Type 2 Diabetes Progression, and Markers of Glycemia and Dyslipidemia Among Puerto Rican Adults With Overweight and Obesity

115. Publication of observational studies making claims of causation over time

116. Long-term impact of COVID-19 hospitalisation among individuals with pre-existing airway diseases in the UK: a multicentre, longitudinal cohort study – PHOSP-COVID

117. Assessing patient risk, benefit and outcomes in drug development: an observational study of regorafenib clinical trials

119. A controlled evaluation of social prescribing on loneliness for adults in Queensland: 8-week outcomes

120. Correction: Discovery and validation of plasma, saliva and multi-fluid plasma–saliva metabolomic scores predicting insulin resistance and diabetes progression or regression among Puerto Rican adults

121. Mathematical Proficiency as the Basis for Assessment: A Literature Review and Its Potentialities

122. Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis.

123. Financial conflicts of interest of OncoAlert: An informal oncology professional network

124. Association Between US Drug Price and Measures of Efficacy for Oncology Drugs Approved by the US Food and Drug Administration From 2015 to 2020.

125. FDA validation of surrogate endpoints in oncology: 2005–2022

126. Estimation of time cost of anti-cancer drugs approved based on comparisons to best supportive care: A cross sectional analysis

129. Time to Event Surrogate Endpoints in Multiple Myeloma Randomized Trials from 2005-2019: A Surrogacy Analysis

130. Brentuximab Vedotin in Advanced Hodgkin’s Lymphoma

131. What drives cancer clinical trial accrual? An empirical analysis of studies leading to FDA authorisation (2015–2020)

132. Development and validation of metrics for assessment of ultrasound-guided fascial block skills☆

134. To degas or not to degas? The effectiveness of pharmaceuticals in reducing the impact of bowel volume variations during liver SBRT treatment

135. Match running performance is influenced by possession and team formation in an English Premier League team

136. Wild European Starlings (Sturnus vulgaris) Make and Use Woolen Tools

139. AI Applications in Adult Stroke Recovery and Rehabilitation: A Scoping Review Using AI

140. Understanding Leadership from the Inside: Using Ethnographic Methods to Examine How the Interplay between Leaders, Followers, and Group Context Shapes Leadership Outcomes

141. Targeted therapy in lung cancer: Are we closing the gap in years of life lost?

142. Dose modification rules and availability of growth factor support: A cross-sectional study of head-to-head cancer trials used for US FDA approval from 2009 to 2021.

144. The frequency of assessment of progression in randomized oncology clinical trials.

146. Time Conquered

148. Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

149. Cognitive and psychiatric symptom trajectories 2–3 years after hospital admission for COVID-19: a longitudinal, prospective cohort study in the UK

Catalog

Books, media, physical & digital resources